Zeta --
Here is the relevant text from the WSJ article cited in the response to your post...
<The top stock picker in the Best on the Street survey was Philip Nadeau, a 31-year-old former neurobiologist now at SG Cowen Securities Corp., a unit of Societe Generale Group of France. A "buy" rating on Introgen Therapeutics Inc., an Austin, Texas, company working on gene-based cancer treatments, yielded 223% for the part of 2003 he recommended it. Most of that gain came in early June, as Introgen reported promising early-stage data for several of its cancer treatments. Dr. Nadeau quickly switched to a "hold," capturing most of the stock's 294% bounce for the full year.
He also had a big hit with Esperion Therapeutics Inc., whose shares returned 147% after he rated them a "buy" in August -- mostly because Pfizer Inc. agreed to acquire the biotech firm and its promising cardiovascular drugs at a significant premium late in the year.
His tops picks for 2004 include Encysive Pharmaceuticals Inc., in Bellaire, Texas, which is expected to report results of clinical trials of a new blood-pressure drug in the second half, and San Diego-based Neurocrine Biosciences Inc., which is expected to launch a new insomnia drug with Pfizer next year.> |
